Summary: Researchers have created a closed-loop, adaptive deep brain stimulation (aDBS) system that senses and responds to walking signals in real time. Unlike traditional continuous DBS, which delivers a constant stream of stimulation and often does not prevent gait problems such as freezing or falls, this new device adjusts stimulation within fractions of a second to match each phase of a person’s stride.
By embedding predictive neural algorithms directly into an implanted neurostimulator, the system continuously monitors the distinct electrical patterns associated with left and right leg movement during walking. Operating autonomously—without relying on an external computer—the implant updates stimulation on a step-by-step basis, functioning like an intelligent “brain pacemaker” that synchronizes with the patient’s motion.
Key Facts
- The stride-by-stride pacemaker analogy: The UCSF device works similarly to a modern cardiac pacemaker, but instead of tracking heart rhythm, its algorithms track the brain’s walking-related rhythms to trigger timely stimulation bursts.
- Limitations of continuous stimulation: More than ten million people worldwide live with Parkinson’s disease. Continuous deep brain stimulation can be effective for tremor and rigidity, but it often falls short in addressing gait impairment, freezing of gait, and fall risk.
- Bilateral left-right neural mapping: The research team identified individualized neural signatures that correspond to lifting and planting the left or right foot. These signatures are programmed into the implanted device so it can make micro-adjustments on a step-by-step basis.
- Laboratory and real-world validation: In controlled laboratory tests, aDBS improved spatial gait symmetry and reduced variability in walking patterns. Blinded, multi-day crossover trials in participants’ home environments confirmed fewer falls when the adaptive system was active.
- Dual cortical–subcortical sensing: Trial participants received both deep subcortical stimulation leads and investigational cortical electrodes placed over movement-related areas, enabling the system to read clear intentional movement signals while delivering targeted stimulation.
- Shift toward behaviorally driven feedback: Prior adaptive neurotherapies have typically responded to slower biological markers such as medication cycles or sleep patterns. This approach links stimulation directly to fast, millisecond-scale behavior.
- Potential for personalized neuromodulation: Demonstrating that an implant can sense and respond dynamically to real-time actions opens the path to personalized, responsive therapies for other conditions such as speech disorders, treatment-resistant depression, and cognitive decline.
Source: UCSF
UC San Francisco researchers have developed a new form of deep brain stimulation (DBS) that automatically adjusts as a person walks, improving gait and reducing falls for people with Parkinson’s disease.
Published June 15 in Nature Medicine, the study shows for the first time that an implanted stimulator can detect step-related neural signals and adjust stimulation within fractions of a second. Operating like a pacemaker for walking, the system times stimulation to the brain’s movement rhythms to support each step.
“Difficulty walking is one of the most disabling symptoms of Parkinson’s disease and one of the hardest to treat,” said Doris D. Wang, MD, PhD, associate professor of neurological surgery at UCSF and the study’s senior author. “Walking is a highly dynamic behavior that requires precise timing across both sides of the body. We developed a system that recognizes those movement patterns and responds in real time, allowing stimulation to work with the patient as they move.”
A smarter kind of brain stimulation
Parkinson’s disease affects millions worldwide. While conventional DBS often reduces tremor and stiffness, gait impairment, freezing, and falls commonly remain. The UCSF team reasoned that one shortcoming of continuous DBS is its static output: a constant stimulation pattern that cannot adapt to the rapid, step-by-step demands of walking.
To address that gap, researchers created a personalized adaptive DBS (aDBS) system that identifies neural signals tied to left- and right-leg movements. These personalized signatures are embedded in the implanted neurostimulator so the device can automatically change stimulation during each phase of walking without an external computer.
“The brain contains remarkably rich information about movement,” said Kenneth H. Louie, PhD, a UCSF postdoctoral scholar and the paper’s first author. “We identified neural signatures linked to each step and used them to guide stimulation in real time.”
From constant therapy to responsive therapy
The trial enrolled five people with Parkinson’s disease who had prior DBS surgery and were participating in a UCSF research program using an investigational system. In addition to standard therapeutic leads implanted deep in the brain, participants received research electrodes over movement-related cortical areas. Combined, these sensors allowed clinicians to identify individualized gait biomarkers and program the stimulator to adapt automatically during walking.
In laboratory testing, the aDBS system improved step symmetry and reduced variability in gait—indicators of more stable and efficient walking. Participants then completed blinded, multi-day crossover testing during their normal daily routines. When the adaptive system was active, participants experienced fewer falls while overall Parkinson’s symptom control was maintained. No serious adverse events were reported, and patients tolerated the rapid adjustments well.
While larger studies are needed, these early results suggest that timing stimulation to behavior can yield benefits beyond continuous stimulation.
A new frontier for personalized neuromodulation
This work reframes how brain stimulation therapies can be designed. Most earlier adaptive DBS approaches have relied on slowly changing markers of disease state. The UCSF method ties stimulation directly to behavior, demonstrating that implants can respond to real-time actions.
“This study is about more than walking,” Wang said. “It shows that brain stimulation can adapt to what a person is doing in real time. That opens the door to therapies that respond dynamically to movement, speech, mood, cognition, and other brain functions.”
Researchers anticipate a future in which implanted devices continuously sense neural activity and deliver personalized therapy only when and where it is needed.
“Instead of delivering the same stimulation all day, future devices may listen to the brain and respond immediately to a patient’s needs,” Wang added. “Just as pacemakers transformed heart care, intelligent neurostimulators may transform treatment for brain disorders.”
Additional UCSF Authors: Kenneth H. Louie, PhD; Jannine P. Balakid, BS; Jessica E. Bath, DPT, PhD; Seongmi Song, PhD; Hamid Fekri Azgomi, PhD; Jacob H. Marks, BA; Philip A. Starr, MD, PhD.
Additional Author: Julia T. Choi, PhD (University of Florida, Gainesville).
Funding: This study was supported by the Michael J. Fox Foundation (Grant MNS135499A), the UCSF Burroughs Wellcome Fund Career Award for Medical Scientists, National Institute of Neurological Disorders and Stroke (NIH/NINDS) grant 1R01NS130183, and UCSF Catalyst Grants. Funding was obtained by D.D.W.
Disclosures: D.D.W. consults for Medtronic, Boston Scientific, and Iota Bioscience and receives research support from Boston Scientific. P.A.S. receives support from Medtronic and Boston Scientific for fellowship education. K.H.L. is a current employee of Echo Neurotechnologies; his contributions to this study were completed prior to employment there, and Echo Neurotechnologies played no role in study design, data collection, analysis, or the decision to publish.
Key Questions Answered:
A: Walking is a rapid, continuously changing behavior that requires millisecond-precise coordination between brain, spinal cord, and muscles on both sides of the body. Conventional DBS provides a steady, unvarying stream of stimulation. Because that static output cannot adjust to the fast, step-by-step demands of walking, it often does not help the brain coordinate movements needed to prevent freezing or falls.
A: The research electrodes read movement-related electrical signals from cortical and subcortical areas. The team identified distinct, repeatable neural signatures tied to intended left- and right-leg movements. By programming those individualized signatures into the implanted neurostimulator, the device recognizes step-specific signals in real time and adjusts stimulation to match the patient’s movements.
A: This study is an important early clinical milestone but remains small and exploratory. It demonstrated safety and feasibility in five closely monitored participants and succeeded during real-world testing. These results support larger, multi-center trials needed for regulatory approval, which typically take several years.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The journal paper was reviewed in full.
- Additional context was added by staff.
About this neurotech and Parkinson’s disease research news
Author: Brooke Thornton
Source: UCSF
Contact: Siyun Qin – Brooke Thornton
Image: The image is credited to Neuroscience News
Original Research: Open access. “Adaptive Deep Brain Stimulation for Dynamic Gait Control in Parkinson’s Disease: a randomized feasibility trial” by Kenneth H. Louie et al., published in Nature Medicine. DOI: 10.1038/s41591-026-04434-2
Abstract
Adaptive Deep Brain Stimulation for Dynamic Gait Control in Parkinson’s Disease: a randomized feasibility trial
A randomized crossover study of five patients with Parkinson’s disease shows that gait-synchronized adaptive deep brain stimulation is feasible and safe, and that it reduces falls compared with continuous stimulation. Gait dysfunction in Parkinson’s disease is a major source of disability and is often inadequately treated by continuous DBS.
While adaptive DBS has demonstrated benefits for other motor symptoms using state-driven neural signals, gait is a dynamic, cyclical behavior that may need temporally precise modulation. This trial evaluated a behavior-contingent aDBS method that synchronizes stimulation to the gait phase.
In a single-center, blinded, randomized crossover study, researchers identified patient-specific biomarkers from cortical or pallidal field potentials in all five participants and embedded those biomarkers into a bidirectional neurostimulator. Acute in-clinic testing showed improvements in step variability and step symmetry versus continuous DBS. Three participants then completed a double-blinded, multi-day crossover phase in everyday settings, where aDBS maintained general motor control, reduced falls, and produced individualized gait improvements. No adverse events occurred, and aDBS was well tolerated. These findings support larger randomized trials to determine clinical efficacy.
ClinicalTrial.gov registration: NCT04675398.